Top

Published in:

01-04-2019 | Research Article

Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens

Authors: I. Blancas, E. Aguirre, S. Morales, M. L. Gonzálvez, S. Servitja, N. Díaz, S. del Barco, A. Barnadas, M. Margelí, I. García Carbonero, A. Llombart

Published in: Clinical and Translational Oncology | Issue 4/2019

Abstract

Purpose

To evaluate the efficacy and safety of oral weekly vinorelbine 60 mg/m² for metastatic breast cancer (MBC) in patients previously treated with anthracyclines or taxanes in routine clinical practice.

Materials and methods

Fifty-five patients were enrolled in a prospective multicentre study conducted in Spain. Women ≥ 18 years of age with locally advanced breast cancer who were not candidates for surgical treatment with a radical intention or patients with stage IV disease, and who had received a prior taxane or anthracycline regimen were eligible for participation.

Results

Median age was 67 years. Median progression-free survival was 3.7 months (95% CI 2.5–4.9), median overall survival 10 months (95% CI 6.6–13.5), and overall response rate and clinical benefit rate were 29.1% and 49.1%, respectively. Main grade 3 and 4 toxicities were neutropenia 9.1%, febrile neutropenia 3.6% and constipation 3.6%. In total, 86% of the patients received complete treatment without delays or dose reduction. Moreover, HER2-positive patients who received oral vinorelbine concomitantly with trastuzumab showed better response (complete response: HER2-positive 14.3% vs. HER2-negative 0%; partial response: HER2-positive 42.9% vs. HER2-negative 25.6%; p = 0.008), better disease control rate (HER2-positive 100% vs. HER2-negative 46.2%; p = 0.011), and better values for the remaining analysed variables than HER2-negative patients.

Conclusion

Our study provides real-world data on the use of oral weekly vinorelbine, which proves an effective and well-tolerated regimen for MBC patients previously treated with taxanes or anthracyclines. Patients with HER2-positive disease could also benefit from this treatment in combination with trastuzumab.

Rabow M, Small R, Jow A, Majure M, Chien A, Melisko M, et al. The value of embedding: integrated palliative care for patients with metastatic breast cancer. Breast Cancer Res Treat. 2018;167(3):703–8. https://doi.org/10.1007/s10549-017-4556-2.CrossRefPubMed

Fedele P, Ciccarese M, Surico G, Cinieri S. An update on first line therapies for metastatic breast cancer. Expert Opin Pharmacother. 2018;19(3):243–52. https://doi.org/10.1080/14656566.2018.1425680.CrossRefPubMed

Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14(8):2197–205.CrossRefPubMed

Cancer B. Fact sheet. 2016. http://www.moph.gov.lb/Campaigns/Materials/FactSheet.pdf. Accessed 07 May 2018.

Heinemann V, Di Gioia D, Vehling-Kaiser U, Harich HD, Heinrich B, Welt A, et al. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Ann Oncol. 2011;22(3):603–8. https://doi.org/10.1093/annonc/mdq409.CrossRefPubMed

National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology V. 1. 2010. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.

Palmieri C, Krell J, James CR, Harper-Wynne C, Misra V, Cleator S, et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol. 2010;7(10):561–74. https://doi.org/10.1038/nrclinonc.2010.122.CrossRefPubMed

Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, et al. Advances in systemic therapy for metastatic breast cancer: future perspectives. Med Oncol (Northwood, London, England). 2017;34(7):119. https://doi.org/10.1007/s12032-017-0975-5.CrossRef

Potier P. The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol. 1989;16(2 Suppl 4):2–4.PubMed

10.

Binet S, Chaineau E, Fellous A, Lataste H, Krikorian A, Couzinier JP, et al. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer. 1990;46(2):262–6.CrossRefPubMed

11.

Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993;11(7):1245–52.CrossRefPubMed

12.

Garcia-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol. 1994;5(9):854–7.CrossRefPubMed

13.

Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15(1):110–5.CrossRefPubMed

14.

Depierre A, Freyer G, Jassem J, Orfeuvre H, Ramlau R, Lemarie E, et al. Oral vinorelbine: feasibility and safety profile. Ann Oncol. 2001;12(12):1677–81.CrossRefPubMed

15.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.CrossRefPubMed

16.

Aapro M, Finek J. Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. Cancer Treat Rev. 2012;38(2):120–6. https://doi.org/10.1016/j.ctrv.2011.05.005.CrossRefPubMed

17.

Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 2003;21(1):35–40. https://doi.org/10.1200/jco.2003.09.057.CrossRefPubMed

18.

Trillet-Lenoir V, Sommer H, Delozier T, Koralewski P, Ruiz Simon A, Lichinister M, et al. Oral vinorelbine in metastatic breast cancer: long term results of 2 phase II studies. Eur J Cancer. 2004;2(3):137 (Supplement).CrossRef

19.

Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Locker GJ, et al. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer Chemother Pharmacol. 2006;57(5):554–8. https://doi.org/10.1007/s00280-005-0092-6.CrossRefPubMed

20.

Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM, et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. Ann Oncol. 2006;17(4):623–9. https://doi.org/10.1093/annonc/mdj130.CrossRefPubMed

21.

Steger GG, Dominguez A, Dobrovolskaya N, Giotta F, Tubiana-Mathieu N, Pecherstorfer M, et al. Single-agent oral vinorelbine as first-line chemotherapy for endocrine-pretreated breast cancer with bone metastases and no visceral involvement: NORBREAST-228 Phase II Study. Clin Breast Cancer. 2018;18(1):e41–7. https://doi.org/10.1016/j.clbc.2017.05.012.CrossRefPubMed

22.

Cazzaniga ME, Cortesi L, Ferzi A, Scaltriti L, Cicchiello F, Ciccarese M, et al. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res Treat. 2016;160(3):501–9. https://doi.org/10.1007/s10549-016-4009-3.CrossRefPubMedPubMedCentral

23.

Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, et al. Taxanes plus trastuzumab compared to oral vinorelbine plus trastuzumab in HER2-overexpressing metastatic breast cancer. Breast care (Basel, Switzerland). 2014;9(5):344–8. https://doi.org/10.1159/000368330.CrossRef

24.

Chen TW, Yeh DC, Chao TY, Lin CH, Chow LW, Chang DY, et al. A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. Jpn J Clin Oncol. 2018;48(3):242–7. https://doi.org/10.1093/jjco/hyx188.CrossRefPubMed

25.

Farhat F, Kattan JG, Ghosn M. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer. Cancer Chemother Pharmacol. 2016;77(5):1069–77. https://doi.org/10.1007/s00280-016-3027-5.CrossRefPubMed

26.

Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011;29(3):264–71. https://doi.org/10.1200/JCO.2010.30.8213.CrossRefPubMed

27.

Mansour M, Mourad C. Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer. Cancer Chemother Pharmacol. 2013;72(2):429–35. https://doi.org/10.1007/s00280-013-2216-8.CrossRefPubMed

28.

Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer. 2008;62(1):85–91. https://doi.org/10.1016/j.lungcan.2008.02.009.CrossRefPubMed

29.

Barni S, Freier B, Garau I, Mouysset JL, Sediva M, Zamagni C, et al. Burden of advanced breast cancer for patients and caregivers in Europe: comparison of two treatment forms of vinorelbine, oral and intravenous. Curr Med Res Opin. 2016;32(11):1807–12. https://doi.org/10.1080/03007995.2016.1211518.CrossRefPubMed

30.

Welt A, Meldgaard P, Martoni A, Hansen O, Gebbia V, Fischer von Weikersthal L, et al. Improving chemotherapy capacity by switching from IV to oral vinorelbine. Eur J Oncol Pharm. 2010;4(3):14–8.

Title: Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens
Authors: I. Blancas
E. Aguirre
S. Morales
M. L. Gonzálvez
S. Servitja
N. Díaz
S. del Barco
A. Barnadas
M. Margelí
I. García Carbonero
A. Llombart
Publication date: 01-04-2019
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 4/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-018-1946-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2019

Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis

A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study

Modulation of cancer cells’ radiation response in the presence of folate conjugated Au@Fe2O3 nanocomplex as a targeted radiosensitizer

Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology

Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies

Quality indicators in radiation oncology: proposal of the Spanish Society of Radiation Oncology (SEOR) for a continuous improvement of the quality of care in oncology

Keynote webinar | Spotlight on antibody–drug conjugates in cancer